Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company, has granted inducement awards to eleven new employees under its 2024 Inducement Plan. The awards consist of time-based restricted stock units (RSUs) for 32,600 shares of common stock.
The RSUs will vest in three equal installments on March 1 of 2026, 2027, and 2028, contingent upon continued employment. These equity awards were granted outside of Intellia's stockholder-approved plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these awards as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), un'azienda di editing genetico in fase clinica, ha concesso premi di indennità a undici nuovi dipendenti nell'ambito del suo Piano di Indennità 2024. I premi consistono in unità di azioni riservate (RSU) basate sul tempo per 32.600 azioni di azioni ordinarie.
Le RSU matureranno in tre rate uguali il 1° marzo del 2026, 2027 e 2028, a condizione di un'occupazione continuativa. Questi premi azionari sono stati concessi al di fuori dei piani approvati dagli azionisti di Intellia attraverso il Piano di Indennità 2024, adottato dal consiglio a giugno 2024. Il comitato per la compensazione ha approvato questi premi come indennità materiale per l'occupazione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), una empresa de edición genética en etapa clínica, ha otorgado premios de inducción a once nuevos empleados bajo su Plan de Inducción 2024. Los premios consisten en unidades de acciones restringidas (RSU) basadas en el tiempo para 32,600 acciones de acciones ordinarias.
Las RSU se consolidarán en tres cuotas iguales el 1 de marzo de 2026, 2027 y 2028, condicionadas a la continuidad del empleo. Estos premios de acciones se otorgaron fuera de los planes aprobados por los accionistas de Intellia a través del Plan de Inducción 2024, que fue adoptado por la junta en junio de 2024. El comité de compensación aprobó estos premios como un incentivo material para el empleo de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
인텔리아 테라퓨틱스 (NASDAQ:NTLA), 임상 단계의 유전자 편집 회사가 2024 유도 계획에 따라 11명의 신규 직원에게 유도 보상을 부여했습니다. 이 보상은 32,600주의 보통주에 대한 시간 기반 제한 주식 단위(RSU)로 구성됩니다.
RSU는 2026년, 2027년, 2028년 3월 1일에 세 번에 걸쳐 균등하게 배분되며, 지속적인 고용이 조건입니다. 이러한 주식 보상은 2024 유도 계획을 통해 인텔리아의 주주 승인 계획 외부에서 부여되었습니다. 이 계획은 2024년 6월 이사회에 의해 채택되었습니다. 보상 위원회는 이 보상을 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용을 위한 실질적인 유인으로 승인했습니다.
Intellia Therapeutics (NASDAQ:NTLA), une entreprise de modification génétique en phase clinique, a accordé des primes d'incitation à onze nouveaux employés dans le cadre de son Plan d'Incitation 2024. Les primes consistent en unités d'actions restreintes (RSU) basées sur le temps pour 32 600 actions ordinaires.
Les RSU seront acquises en trois versements égaux le 1er mars 2026, 2027 et 2028, sous réserve d'un emploi continu. Ces primes en actions ont été accordées en dehors des plans approuvés par les actionnaires d'Intellia par le biais du Plan d'Incitation 2024, qui a été adopté par le conseil d'administration en juin 2024. Le comité de rémunération a approuvé ces primes comme incitation matérielle à l'emploi conformément à la règle d'inscription Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), ein Unternehmen für Genbearbeitung in der klinischen Phase, hat elf neuen Mitarbeitern im Rahmen seines Induktionsplans 2024 Anreize gewährt. Die Anreize bestehen aus zeitbasierten eingeschränkten Aktieneinheiten (RSUs) für 32.600 Aktien des Stammkapitals.
Die RSUs werden in drei gleichen Raten am 1. März 2026, 2027 und 2028 fällig, abhängig von einer fortgesetzten Beschäftigung. Diese Eigenkapitalanreize wurden außerhalb der von den Aktionären genehmigten Pläne von Intellia im Rahmen des Induktionsplans 2024 gewährt, der im Juni 2024 vom Vorstand angenommen wurde. Der Vergütungsausschuss genehmigte diese Anreize als wesentlichen Anreiz für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- Successful recruitment of 11 new employees indicating company growth
- 32,600 new shares creating minor dilution for existing shareholders
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on March 1, 2025, it awarded an inducement grant to eleven new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 32,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on March 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
This press release was published by a CLEAR® Verified individual.
FAQ
How many shares were granted in Intellia's (NTLA) March 2025 inducement awards?
What is the vesting schedule for Intellia's (NTLA) March 2025 inducement RSUs?
When did Intellia Therapeutics adopt its 2024 Inducement Plan?
Under which Nasdaq rule were Intellia's (NTLA) inducement grants approved?
